The effectiveness of the Pfizer-BioNTech COVID-19 vaccine falls below 50 percent after five months, according to a new study published in The Lancet medical journal on Oct. 4.
The study (pdf), which was funded by Pfizer, aimed to evaluate the overall variant-specific effectiveness of the companies’ vaccine against CCP (Chinese Communist Party) virus infections and COVID-19-related hospital admissions over time.
